Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome
Open Access
- 29 May 2007
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 9 (3), R33
- https://doi.org/10.1186/bcr1681
Abstract
We investigated whether mRNA levels of E2F1, a key transcription factor involved in proliferation, differentiation and apoptosis, could be used as a surrogate marker for the determination of breast cancer outcome.Keywords
This publication has 33 references indexed in Scilit:
- Concordance among Gene-Expression–Based Predictors for Breast CancerNew England Journal of Medicine, 2006
- Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?Journal of Clinical Oncology, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Prognostic value of proliferation in invasive breast cancer: a reviewJournal of Clinical Pathology, 2004
- Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and WoundsPLoS Biology, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- The Hallmarks of CancerCell, 2000
- Angiogenesis and metastasisEuropean Journal Of Cancer, 1996